News

HDA UK Media And Political Bulletin – 5 July 2017

MEDIA SUMMARY 

Group behind delivery safety review sets out next priorities
Chemist and Druggist, Grace Lewis, 5 July, 2017

The Community Pharmacy Patient Safety Group has released a joint report with the National Pharmacy Association (NPA) examining best practices in medicine delivery. The group aims to improve delivery and distribution, as well as improving the reporting of patient safety incidences. They examined in particular how to improve children’s safety. The report looked at improving lettering on prescriptions and figuring out ways that drug packaging could be improved to reduce dispensing errors and over-prescription.

ABPI respond to statement of UK Government’s medicines regulation plans
European Pharmaceutical Review, 4 July, 2014 

The European Pharmaceutical Review continued coverage of Jeremy Hunt’s and Greg Clark’s letter to the Financial Times regarding the pharmaceutical industry. In the response letter from the Association of the British Pharmaceutical Industry (ABPI) Mike Thompson, APBI CEO, stated that the letter was “a welcome recognition that the future of medicines regulation is a key priority”. The article also noted that the ABPI are at the heart of establishing a “consensus on key Brexit issues” such as trade and science research. The work encompasses over 200 experts, leading academic and public institutions as well as several regulatory agencies.

PARLIAMENTARY COVERAGE

There is no parliamentary coverage.

FULL COVERAGE 

Group behind delivery safety review sets out next priorities
Chemist and Druggist, Grace Lewis, 5 July, 2017

The Community Pharmacy Patient Safety Group has set out its next priorities, following the publication of its review of medicines delivery services.

The group (see more details below), which consists of representatives of all of the larger pharmacy chains, as well as the National Pharmacy Association (NPA), published a report on best practices for medicines delivery services last month.

As well as delivery services, the group’s other priorities include working with the NHS to improve the systems by which pharmacies can report patient safety incidences, as well as creating “top tips around dispensing children’s medicine”, according to Company Chemists’ Association senior policy adviser Kate Livesey, who provides secretariat support for the group.

“Children are one of the most vulnerable patient groups. So that is an area we’re focusing on, because different pharmacies do things in different ways,” Ms Livesey told C+D last Friday (June 30).

“There’s a really simple tip somebody mentioned the other week, which was…using a stamp that said ‘child’ in red ink. Every time a prescription came in for somebody who was under 14, they stamped it.”

“It draws the team’s attention to that script in a different way,” Ms Livesey said. “They think about the small person behind the prescription, rather than potentially just seeing a piece of paper.”

The group will also follow up on some of the issues featured in the NPA’s medication safety officer’s reports, Ms Livesey explained.

“Everyone just accepts [what] the most common errors in [pharmacies] are. But we don’t want to accept that.”

As well as “looking at lettering on prescriptions”, she added that the group will consider if there is “a different way dispensaries can be organised that would help reduce the likelihood of some of those errors?”.

“It’s recognising that packaging…will be a contributory factor, but there may be other things that come into it – especially human factors.”

ABPI respond to statement of UK Government’s medicines regulation plans
European Pharmaceutical Review, 4 July, 2014 

The ABPI has responded to a joint letter from Jeremy Hunt, Secretary of State for Health, and Greg Clark, Secretary of State for Business, published by the Financial Times, that outlined the UK Government’s plans for the regulation of medicines as the UK leaves the European Union (EU).

In the response from the Association of the British Pharmaceutical Industry, Mike Thompson, ABPI Chief Executive said:
“This letter is a welcome recognition that the future of medicines regulation is a key priority for the Government as we negotiate a new relationship with the EU. It also signals a readiness to take a pragmatic approach to Brexit negotiations that puts people’s health first. This is a great first step and we look forward to seeing more detail in the coming weeks and months.

ABPI aims to strengthen UK Life Sciences

The Association of the British Pharmaceutical Industry (ABPI) are at the heart of a health sector-wide effort, post-Referendum, that aims to establish consensus on key Brexit issues such as a regulation, trade, immigration and UK science. This has been to ensure that patients and public health are central to Brexit negotiations, and that UK Life Sciences is in as strong a position as possible as the UK establishes a new relationship with Europe.

UK life sciences sector productivity doubles national average

This work is ongoing, and continues to involve more than 200 global experts from leading pharmaceutical and biotech companies; leading academic groups and research charities (such as the Wellcome Trust); the UK’s Medicines and Healthcare products Regulatory Agency (MHRA); the NHS and Public Health England; as well as a vast range of UK Government departments.

HDA UK Media And Political Bulletin – 5 July 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?